Bayer made much of its desire to establish a cell therapy pipeline on August 8 when it announced it would shell out up to $600 million to acquire full control of BlueRock Therapeutics. But the deal is just the latest example of growing interest by biopharma giants in applying gene editing toward new treatments.
{iframe}https://www.genengnews.com/a-lists/top-10-companies-leveraging-gene-editing-in-2019/?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20190815&oly_enc_id=5901D8426578G1Y{/iframe}